Delisting riskPopularity #5,120
Iridex (IRIX)
Laser systems and procedure probes for glaucoma and retinal care.
$0.6355
After hours+0.00 (+0.39%)
At close$0.6330(−1.56%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Jan 2026 | Q1 FY26Apr 2026 | Q2 FY26Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13 | 12 | 12 | 13 | 12 | 13 | 12 | 14 | 12 | 15 | 12 | 13 |
| Cost of revenue | 7 | 8 | 7 | 7 | 7 | 7 | 7 | 9 | 8 | 9 | 7 | 8 |
| Gross profit | 6 | 5 | 4 | 5 | 4 | 6 | 5 | 5 | 4 | 6 | 5 | 4 |
| 7 | 8 | 8 | 8 | 6 | 6 | 5 | 6 | 5 | 6 | 5 | 5 | |
| Research & development | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | |
| Selling & marketing | 4 | 4 | 4 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 |
| General & administrative | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −2 | −3 | −3 | −3 | −2 | −1 | 0 | −1 | −1 | 0 | 0 | −1 |
| 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −2 | −3 | −3 | −3 | −2 | −1 | −2 | −1 | −2 | 0 | 0 | −1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −2 | −3 | −3 | −3 | −2 | −1 | −2 | −1 | −2 | 0 | −1 | −1 |
| Net income | −2 | −3 | −3 | −3 | −2 | −1 | −2 | −1 | −2 | 0 | −1 | −1 |
| EPS, basic | −$0.11 | −$0.18 | −$0.21 | −$0.16 | −$0.12 | −$0.05 | −$0.10 | −$0.06 | −$0.09 | −$0.01 | −$0.03 | −$0.07 |
| EPS, diluted | −$0.11 | −$0.18 | −$0.21 | −$0.16 | −$0.12 | −$0.05 | −$0.10 | −$0.06 | −$0.09 | −$0.01 | −$0.03 | −$0.07 |
| Weighted average shares, basic | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Weighted average shares, diluted | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| EBITDA | −1 | −2 | −3 | −2 | −2 | 0 | −1 | −1 | −1 | 0 | 0 | −1 |
| Depreciation & amortization | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −2 | −3 | −3 | −3 | −2 | −1 | −2 | −1 | −2 | 0 | 0 | −1 |
